ArticleBMJ open2025

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.

Lulu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.